March 2018

The Vallabhbhai Patel Chest Institute (VPCI) is a unique postgraduate medical institution devoted to research, teaching and patient care in the field of chest diseases. It is a University of Delhi maintained institution and is funded entirely by the Ministry of Health and Family Welfare, Government of India. The Institute is ideally located in the heart of the main campus of the University of Delhi, providing the requisite academic environment. The Institute fulfills the national need for providing relief to large number of patients in the community suffering from Chest Diseases. It has eminently discharged its role and has earned a unique place in the field of Chest Medicine.

Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection.

This is a question we’ve asked ourselves over and over. It’s how we at Medtronic have made hearts beat stronger and longer. It’s how we’ve pushed the limits of what technology can do in and for the body. It’s how we will continue to alleviate pain, restore health and extend life. Rising costs, an aging population, and the burden of chronic disease impact us all. And no single entity in the healthcare system can solve these challenges alone. That’s why we’re stepping forward. That’s why we’re prepared to put the full power of our technologies, services, resources — and our people — to work with new partners, in new ways, to usher in a new era in healthcare.

Post : Sales Representative I

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Post : Scientist, Biologics Product Development

Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments. Headquartered in Copenhagen, Denmark, Xellia has global facilities in Europe, North America, and Asia, currently employing over 1700 people. With over 100 years of industry experience in developing last resort treatments for infectious diseases, Xellia is focused on the supply of products which not only save lives, but also improve and enhance patients’ quality of life. Together with us, you can help lead the fight against bacterial infections.

Post : Validation Scientist